# Mechanism and Evidence: GHK-Cu, BPC-157, and TB-500 in the Peer-Reviewed Literature > BPC-157 TB-500 GHK-Cu blend: mechanisms, preclinical findings, and safety signals across angiogenesis, soft-tissue repair, collagen synthesis, and wound healing. Cited from the peer-reviewed literature. ## BPC-157 Mechanism of Action BPC-157 upregulates VEGFR2 (vascular endothelial growth factor receptor 2), activates the downstream VEGFR2-Akt-eNOS signaling axis, modulates nitric oxide synthesis, and promotes fibroblast and tendon cell proliferation via growth hormone receptor upregulation and JAK2 signaling [1][2][3]. In human vascular endothelial cells and a rat hindlimb ischemia model, BPC-157 increased VEGFR2 mRNA and protein expression, raised vessel density, and accelerated blood flow recovery [1]. In isolated rat aorta, BPC-157 induced concentration-dependent vasodilation through an endothelium-dependent, nitric oxide-mediated pathway with no cardiotoxic effects [2]. A 2024 review documents pleiotropic activity encompassing dopamine, serotonin, GABA, and NO systems [25]. A 2025 narrative review confirms the mechanism and notes only three human pilot studies — all reporting no adverse effects — classifying BPC-157 as investigational [21]. ## BPC-157 Wound Healing and Scarring Studies At 10 μg/kg/day intraperitoneally, BPC-157 improved Achilles Functional Index scores, enhanced load capacity and elasticity, increased fibroblast count and collagen formation, and reduced inflammation [4]. In a medial collateral ligament model, the same dose via intraperitoneal, topical, and oral routes produced consistent improvements over 90 days [8]. Topical BPC-157 accelerated alkali-burn wound closure with improved granulation tissue and collagen deposition [6]. A comprehensive review confirms healing of skin wounds, burns, diabetic ulcers, and fistulas with no toxicity [R5]. ## BPC-157 and Hepatic Safety Signals In rats, BPC-157 antagonized diclofenac-induced hepatic injury — normalizing elevated bilirubin, AST, and ALT values and preventing liver weight increase [5]. The signal is hepatoprotective, not hepatotoxic. No peer-reviewed preclinical study has demonstrated hepatotoxicity from BPC-157. ## BPC-157 Cardiovascular Safety BPC-157 induced concentration-dependent vasodilation via the Src-Caveolin-1-eNOS pathway with no cardiotoxic effect; researchers noted potential cardiovascular-protective implications [2]. Three human pilot studies report no adverse cardiovascular events [21]. ## BPC-157 Side Effects in Preclinical Research More than thirty animal models report minimal toxicity. No significant adverse signals via any route [4][8]. Three human pilot studies reported no adverse effects [21]. Theoretical angiogenesis-related concerns in contexts of existing pathological angiogenesis have not been empirically demonstrated at studied doses. ## TB-500 (Thymosin Beta-4 Fragment): Mechanism and Research TB-500 is the synthetic Ac-LKKTETQ fragment of thymosin beta-4 — the major actin-sequestering molecule in mammalian cells. It controls G-actin polymerization, regulates cell motility, downregulates inflammatory cytokines, promotes angiogenesis, supports stem cell maturation, and reduces myofibroblast numbers to limit scar formation [9][19]. Animal studies across dermal, corneal, and cardiac wound models provided the foundation for multicenter clinical trials of thymosin beta-4 [9]. A 2025 study showed superior corneal wound healing and reduced scarring with an engineered tandem TB4 peptide [R4]. ## TB-500 Benefits Observed in Research Models Topical or intraperitoneal thymosin beta-4 improved wound closure in rats: reepithelialization increased 42% at day 4 and 61% at day 7; no toxicity reported [10]. Thymosin beta-4 overexpression in transgenic mice produced faster hair regrowth via Wnt/beta-catenin/Lef-1 and VEGF/MMP-2 signaling [12]. In aged animals, it counteracted age-related decline in angiogenesis [11]. ## TB-500 and Hair Follicle Studies Thymosin beta-4 expressed in hair follicle stem cells regulates stem cell growth, migration, and differentiation [12][13]. No published human clinical trial has specifically studied TB-500 for hair growth. ## GHK-Cu Copper Peptide: Skin, Collagen, and Systemic Repair Studies GHK-Cu is a naturally occurring tripeptide in human plasma, declining from ~200 ng/mL at age 20 to ~80 ng/mL by age 60 [14]. It stimulates collagen synthesis beginning at 10⁻¹² M and maximizing at 10⁻⁹ M — independent of cell proliferation changes [16]. It modulates ~4,000 human genes: 31.2% show ≥50% expression change [15]. A collagen dressing increased collagen production 9-fold in rats [15]. GHK-Cu liposomes shortened wound healing to 14 days in a mouse scald model with 33.1% increased cell proliferation and elevated VEGF/FGF-2 [17]. ## GHK-Cu Anti-Aging Evidence GHK-Cu activates over 4,000 human genes including antioxidant defense and collagen synthesis genes [15]. Topical formulations improved skin density in placebo-controlled human studies [14]. A 2024 review identifies skin permeability as a critical topical delivery limitation and notes a "surprising absence of clinical studies" despite decades of preclinical evidence [26]. ## GHK-Cu and Hair Follicle Activation Studies AHK-Cu (closely related to GHK-Cu) stimulated elongation of human hair follicles ex vivo and proliferation of dermal papilla cells in vitro, elevating VEGF and reducing TGF-beta-1 [18]. Small human studies with topical GHK-Cu showed increased hair density [14]. ## Wound Healing Peptides: How GHK-Cu, BPC-157, and TB-500 Compare BPC-157 shows the strongest data for tendon and gut tissue repair [4][6][8][21]. TB-500/thymosin beta-4 shows strong data for dermal wound closure and cardiac repair — progressed to Phase 3 trials [9][10][11][R4]. GHK-Cu has the broadest gene-modulation evidence with the deepest human data in topical skin studies [14][15][16]. No head-to-head comparison study places all three under identical conditions. Their tissue-repair profiles are complementary rather than redundant. --- Three growing literatures, one reading room — each study pressed and labeled here, sold by no one and prescribed by no one.